3,3'-diindolylmethane

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
3,3'-diindolylmethane
DrugBank Accession Number
DB11875
Background

Diindolylmethane has been used in trials studying the prevention and treatment of SLE, Prostate Cancer, Cervical Dysplasia, Stage I Prostate Cancer, and Stage II Prostate Cancer, among others.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 246.313
Monoisotopic: 246.115698459
Chemical Formula
C17H14N2
Synonyms
  • Diindolylmethane

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as 3-alkylindoles. These are compounds containing an indole moiety that carries an alkyl chain at the 3-position.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Indoles
Direct Parent
3-alkylindoles
Alternative Parents
Substituted pyrroles / Benzenoids / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Hydrocarbon derivatives
Substituents
3-alkylindole / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Heteroaromatic compound / Hydrocarbon derivative / Organic nitrogen compound / Organonitrogen compound / Organopnictogen compound / Pyrrole
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
indoles (CHEBI:50182) / an indole-phytolexin (CPDQT-424)
Affected organisms
Not Available

Chemical Identifiers

UNII
SSZ9HQT61Z
CAS number
1968-05-4
InChI Key
VFTRKSBEFQDZKX-UHFFFAOYSA-N
InChI
InChI=1S/C17H14N2/c1-3-7-16-14(5-1)12(10-18-16)9-13-11-19-17-8-4-2-6-15(13)17/h1-8,10-11,18-19H,9H2
IUPAC Name
3-[(1H-indol-3-yl)methyl]-1H-indole
SMILES
C(C1=CNC2=CC=CC=C12)C1=CNC2=CC=CC=C12

References

General References
Not Available
PubChem Compound
3071
PubChem Substance
347828212
ChemSpider
2963
BindingDB
50239186
RxNav
1603521
ChEBI
50182
ChEMBL
CHEMBL446452
ZINC
ZINC000000187911
Wikipedia
3,3%27-Diindolylmethane

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedPreventionCervical Cancer / Precancerous Conditions1
2CompletedTreatmentProstate Cancer1
2WithdrawnTreatmentFemale Breast Cancer1
1CompletedPreventionHealthy, no Evidence of Disease2
1CompletedTreatmentAdenocarcinoma of Prostate / Prostate Cancer / Stage I Prostate Cancer / Stage II Prostate Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
CapsuleOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00163 mg/mLALOGPS
logP4.4ALOGPS
logP4.26Chemaxon
logS-5.2ALOGPS
pKa (Strongest Acidic)16.52Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count0Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area31.58 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity77.97 m3·mol-1Chemaxon
Polarizability27.58 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-015a-0290000000-b1e393c3273cd53d132b
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-0090000000-ceb92607957d69651d3f
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-0090000000-d9cd6fd409c17afbb8ad
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-0090000000-1cba916cbe7f8c1eca5c
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00kb-0490000000-e0b419589e0a88334b0a
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0uyi-0690000000-f64643e814ba35dd5209
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0900000000-1ea18a87bb6e540a0d95
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-165.9984422
predicted
DarkChem Lite v0.1.0
[M-H]-165.8218422
predicted
DarkChem Lite v0.1.0
[M-H]-152.11417
predicted
DeepCCS 1.0 (2019)
[M+H]+154.50972
predicted
DeepCCS 1.0 (2019)
[M+Na]+160.55391
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 20:56 / Updated at June 12, 2020 16:53